It is expected that the delivery growth rate of Innovative Drugs will significantly increase. The chairman of Yifan Pharmaceutical stated, "The certainty of this year's performance is relatively high" | Direct coverage of the Earnings Conference.

1. Yifan Pharmaceutical expects that the shipment volumes of Yilishu and Yinikang will see significant growth by 2025 during the Earnings Conference. 2. Chairman Cheng Xianfeng stated that the company is expanding into the developed markets of Europe and America through Yilishu, while also continuing to focus on core therapeutic areas and promoting global research and development collaboration for key projects in the pipeline.

cls.cnMay 8 21:08

Core product revenue declines. Where will Guangxi Wuzhou Zhongheng Group's new profit growth points be?| Directly addressing the Earnings Conference.

① Due to the significant drop in price of the company's core product, thrombolytic injection, the performance of Guangxi Wuzhou Zhongheng Group continues to decline. ② The company's management indicated that in addition to internal growth, they will also achieve external expansion through mergers and acquisitions in the future, with a focus on the layout of Traditional Chinese Medicine, research and development, business development, and the supporting medical instruments sector.

cls.cnMay 7 23:55

Holiday reading | The "magic weight loss drug" market with a scale of hundreds of billions is entering a fierce competition stage.

Obesity, a health topic that modern people cannot avoid. As people sweat it out in the gym, feel anxious about numbers on the scale, and struggle repeatedly between dieting and indulging in food, "weight loss drugs" have also become the most profitable Gold avenue in the pharmaceutical industry.

PrismMay 4 14:23

In the first quarter, revenue declined year-on-year. Is Zhangzhou Pientzehuang Pharmaceutical's "An Gong" not selling well? | Interpretations

In the first quarter, Zhangzhou Pientzehuang Pharmaceutical's revenue was 3.142 billion yuan, a year-on-year decrease of 0.92%, marking a decline for two consecutive quarters. The Net income attributable to shareholders of the listed company was 1 billion yuan, an increase of 2.59% year-on-year. The sales of the company's Angong Niuhuang Pill, a representative medication for cardiovascular and cerebrovascular diseases, saw a decline of over 80%.

cls.cnApr 29 22:57

Zhangzhou Pientzehuang Pharmaceutical: First quarter performance is steady, with a significant increase in Cash / Money Market operating cash flow by 72.33%.

In the first quarter, Zhangzhou Pientzehuang Pharmaceutical's performance remained robust, with strong growth in operating cash flow highlighting key points of core competitiveness. Financial performance was stable: the first quarter achieved revenue of 3.142 billion yuan, a slight year-on-year decrease of 0.92%; net income attributable to the parent company was 0.9998 billion yuan, a year-on-year increase of 2.59%; and net profit excluding non-recurring items was 1.005 billion yuan, a year-on-year increase of 1.69%. Cash flow performance was impressive: the net cash flow from operating activities was 0.916 billion yuan, a significant year-on-year increase of 72.33%, mainly due to a reduction in expenditures on commodities. Cost control was notable: selling expenses decreased by 38.5% year-on-year to 1.013 billion yuan, while management and research & development expenses decreased respectively.

wallstreetcnApr 29 16:37

*ST Longjin released its Earnings Reports late at night. This is the second Traditional Chinese Medicine company facing (Delisted) this year.｜Quick read announcement.

① Special Treat Longjin disclosed its Earnings Reports, with revenue of 66.4792 million yuan and Net income of -41.4436 million yuan; ② Due to the negative Net income and revenue insufficient at 0.3 billion, the company may be (Delisted).

cls.cnApr 25 09:55